Crane Company (CR)
(Real Time Quote from BATS)
$151.68 USD
+4.64 (3.16%)
Updated Jul 15, 2024 02:06 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CR 151.68 +4.64(3.16%)
Will CR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CR
Pentair (PNR) to Report Q2 Earnings: What's in the Cards?
Crane (CR) is a Great Momentum Stock: Should You Buy?
CR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why It is Appropriate to Retain Stanley Black (SWK)
Here's Why It is Appropriate to Retain Donaldson (DCI) Now
Crane (CR) Surges 3.1%: Is This an Indication of Further Gains?
Other News for CR
Crane NXT, Co. Announces Dates For Second Quarter 2024 Earnings Release and Earnings Call
Crane Company Announces Date for Second Quarter 2024 Earnings Release and Teleconference
Crane Larger Than S&P 500 Component Henry Schein
Crane NXT, Co. Announces Appointment of Michael Mahan as President of Crane Payment Innovations
J&J's Talvey demonstrates robust long-term response in multiple myeloma